Intermountain Healthcare is taking the lead on starting a new generic drug company. Photo: Intermountain Healthcare

Four not-for-profit hospital systems that own 10% of U.S. hospitals — Intermountain Healthcare, Ascension, SSM Health and Trinity Health — are banding together to create a new generic drug company. The Department of Veterans Affairs also is helping and has expressed interest as a purchaser.

Why it matters: Generic drug makers will have a new competitive threat with this first-of-its-kind hospital venture. Marc Harrison, a doctor and the CEO of Intermountain, said drug shortages and high drug prices spurred this action.

Key quote: "It’s hard to make people better if they don’t have access to the medicines they need," Harrison said in an interview. "To add insult to injury, those medicines are being priced in a way that’s nonsensical."

The details:

  • Executives said for now they aren't disclosing what drugs they will make, fearing generic drug companies would respond by lowering prices now and jacking them up again later.
  • The move is in response to generic drug makers that have raised prices significantly after buying older drugs that lost their patents. Martin Shkreli's price hikes on Daraprim are one of the more infamous examples.
  • "We are not anti-pharma. We only care about the bad guys," Harrison said.
  • The company will be structured as a not-of-profit and still needs FDA and other regulatory approvals.
  • Don't expect the company to build large manufacturing plants. Instead, it likely will contract with existing facilities.
  • A handful of people are advising the new entity, including former Obama administration Medicare and Medicaid chief Don Berwick and Nebraska's former Democratic senator and pharmacist Bob Kerrey.
  • Intermountain was already getting phone calls today from other interested systems.

Context: Generic drug prices have caused a lot of stress for hospitals and patients. But most drug spending is heavily concentrated in branded drugs, not generics. Brand-name drugs account for 72% of drug spending, but only 10% of filled prescriptions.

Go deeper

The Biden blowout scenario

Joe Biden speaks at an outdoor Black Economic Summit in Charlotte yesterday. Photo: Kevin Lamarque/Reuters

Joe Biden or President Trump could win the election narrowly — but only one in a popular and electoral vote blowout. 

Why it matters: A Biden blowout would mean a Democratic Senate, a bigger Democratic House and a huge political and policy shift nationwide.

2 hours ago - Technology

Justice's moves ring Big Tech with regulatory threats

Illustration: Annelise Capossela/Axios

The Department of Justice proposed legislation to curb liability protections for tech platforms and moved a step closer toward an antitrust lawsuit against Google Wednesday.

The big picture: As President Trump faces re-election, lawmakers and regulators are hurriedly wrapping up investigations and circling Big Tech with regulatory threats.

Democrats' mail voting pivot

Illustration: Sarah Grillo/Axios

Democrats spent the early months of the coronavirus pandemic urging their base to vote absentee. But as threats of U.S. Postal Service delays, Team Trump litigation and higher ballot rejection rates become clearer, many are pivoting to promote more in-person voting as well.

Why it matters: Democrats are exponentially more likely to vote by mail than Republicans this year — and if enough mail-in ballots are lost, rejected on a technicality or undercounted, it could change the outcome of the presidential election or other key races.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Subscription failed
Thank you for subscribing!